Trial Profile
Prolonging the Response by Low-dose Rituximab Maintenance Therapy in Immune Thrombocytopenia: a Randomized Placebo-controlled Trial - the PROLONG Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 Nov 2023
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Dexamethasone
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- Acronyms PROLONG
- 06 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 05 Oct 2021 Planned number of patients changed from 100 to 130.
- 09 Jan 2017 New trial record